← Leaderboards
Karen M Cerosaletti
Benaroya Research Inst At Virginia Mason
$1,616,357
Attributed
$3,304,844
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,304,844 · 3
By mechanism
R01$2,532,731 · 1
R21$476,575 · 1
U19$295,538 · 1
Top collaborators
- Peter S Linsley2 shared
- S Alice Long2 shared
Most similar at Benaroya Research Inst At Virginia Mason
Same institution · by research overlap
- Matthew C. Altman$2,143,970
- Peter S Linsley$7,467,441
- Carmen R Mikacenic$5,918,794
- Scott Presnell$845,413
- S Alice Long$5,134,395
Others in their field
Other Rising Stars on “Immune Response”
- Angee Greer · Ppd Development Lp$82,531,927
- Rhea Coler · Seattle Children'S Hospital$35,184,139
- Jason Dickens · Duke University$12,259,409
- Suma Babu · Massachusetts General Hospital$11,004,714
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Anice Lowen · Emory University$9,438,846
Research focus
Immune ResponseCellsImmuneT-LymphocyteCd8-Positive T-LymphocytesAntigensPathway InteractionsIsletMediatingFrequenciesInsulinPreventionInsulin-Dependent Diabetes MellitusAutoreactivityCell TypePreventStructure Of Beta Cell Of IsletCd4 Positive T LymphocytesDependenceDiagnosisPathogenesisPeripheral BloodB-LymphocytesPhenotype
Grant awards (5)
Clonal expansion: a marker of disease activity in stage 1 T1D$1,259,153
R01 · FY2025 · DK
Clonal expansion: a marker of disease activity in stage 1 T1D$1,273,578
R01 · FY2024 · DK
HIPC U19 Adaptive Immunophenotyping Core$295,538
U19 · FY2023 · AI · contact PI
Autoreactive CD4 Tscm Development in Type 1 Diabetes$216,625
R21 · FY2023 · AI · contact PI
Autoreactive CD4 Tscm Development in Type 1 Diabetes$259,950
R21 · FY2022 · AI · contact PI